That seems similar to Milan_Griffes’ approach. However, when we’re comparing ballot measures to other opportunities, I think the relevant cost to EA would be the cost to launch the campaign. That’s what EAs would actually be spending money on and what could be spent on other interventions.
We don’t have to assume away the additional costs of getting the medicine, but that can be factored into the benefit (ie. the net benefit is the gains they would get from the medicine—the gains they lose from giving up the funds to purchase the drugs)
That seems similar to Milan_Griffes’ approach. However, when we’re comparing ballot measures to other opportunities, I think the relevant cost to EA would be the cost to launch the campaign. That’s what EAs would actually be spending money on and what could be spent on other interventions.
We don’t have to assume away the additional costs of getting the medicine, but that can be factored into the benefit (ie. the net benefit is the gains they would get from the medicine—the gains they lose from giving up the funds to purchase the drugs)